Antibiotic susceptibility of bacteria isolated from infections in cats and dogs throughout Europe (2002-2009).
A monitoring program of the pre-treatment susceptibility of clinical isolates of bacteria from diseased dogs and cats was active between the years 2002 and 2009. Susceptibility of each isolated strain to a panel of nine antibiotics (amoxicillin/clavulanic acid, ampicillin, penicillin, clindamycin, doxycycline, enrofloxacin, marbofloxacin, trimethoprim and trimethoprim/sulfamethoxazole) was assessed. The Minimum Inhibitory Concentration (MIC) of marbofloxacin was also determined by a standardized microdilution technique following CLSI recommendations. In total, 1857 bacterial strains were collected throughout Europe from cases of otitis, respiratory, urinary and dermatological infections. Although bacterial susceptibility varied for each of the antibiotics within the panel, patterns of susceptibility were similar to those described in the literature for comparable time periods and geographical areas. With a clinical resistance varying from 0 to 14.48% against the isolated strains, marbofloxacin susceptibility was very high and remains an effective antibiotic for the treatment of otitis, urinary, respiratory and dermatological infections in companion animals.
Vétoquinol S.A., Centre de recherche, 34 rue du Chêne Sainte Anne, 70200 Lure, France.
Stéphane
S
Kroemer
Vétoquinol S.A., Centre de recherche, 34 rue du Chêne Sainte Anne, 70200 Lure, France.
Farid
F
El Garch
Vétoquinol S.A., Centre de recherche, 34 rue du Chêne Sainte Anne, 70200 Lure, France.
Delphine
D
Galland
Vétoquinol S.A., 31 rue des Jeûneurs, 75002 Paris, France.
Jean-Luc
JL
Petit
Vétoquinol S.A., Centre de recherche, 34 rue du Chêne Sainte Anne, 70200 Lure, France.
Frédérique
F
Woehrle
Université ParisEst, UMR 956 Anses/ENVA USC INRA, Microbiologie, École Nationale Vétérinaire d'Alfort, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France. Electronic address: hjboulouis@vet-alfort.fr.
Henri-Jean
HJ
Boulouis
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002371:Cat Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D004285:Dogs; D024901:Drug Resistance, Multiple, Bacterial; D062665:Epidemiological Monitoring / Q000662:veterinary; D005060:Europe / Q000453:epidemiology; D024841:Fluoroquinolones / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary*; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000254:growth & development; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary*; D008826:Microbial Sensitivity Tests; D010031:Otitis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000662:veterinary
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C080260:marbofloxacin
Antimicrobial susceptibility; Cats; Dermatological infection; Dogs; Fluoroquinolone; Marbofloxacin; Otitis; Respiratory; Survey; Urinary